Heart Arrhythmia Drug Repurposed to Combat Antibiotic-Resistant Bacteria
Research from Emory University has discovered that the heart arrhythmia medication fendiline can be repurposed to kill antibiotic-resistant bacteria, offering new hope for treating difficult hospital infections.
A groundbreaking study from Emory University has shed light on a promising new approach to tackling the urgent global issue of antibiotic-resistant infections. These resistant bacteria often spread within hospital settings and pose significant treatment challenges due to the limited number of effective antibiotics available. Focusing on the highly infectious bacterium Acinetobacter baumannii, which primarily affects immunocompromised patients in clinical environments, researchers employed an innovative strategy to identify vulnerabilities specific to resistant bacteria.
The study, published in the Proceedings of the National Academy of Sciences (PNAS), revealed that fendiline, a drug originally used to treat heart arrhythmias by acting as a calcium channel blocker, can effectively kill this pathogen. Fendiline targets the bacterium’s essential lipoprotein trafficking pathway, which is notably weakened in antibiotic-resistant strains. This discovery demonstrates the potential for repurposing existing medications to develop targeted therapies against resistant bacteria.
Dr. Philip Rather, the study’s lead author and professor at Emory University School of Medicine, emphasized the importance of this finding, stating the need for new therapeutics to combat resistant infections commonly seen in ventilated patients and those with deep soft tissue infections. Jennifer Colquhoun, Ph.D., the first author and research scientist, highlighted that this approach exploits a newly identified bacterial weakness, enabling rapid development and deployment of treatment options.
Since fendiline is already FDA-approved, there is a significant advantage in progressing to clinical trials swiftly. Its ability to selectively target the resistant bacteria while sparing beneficial gut flora suggests it could become a valuable addition to the arsenal against difficult-to-treat hospital infections, especially in immunocompromised populations.
This novel approach opens pathways for developing new antibiotics that target similar bacterial vulnerabilities, offering hope for more effective treatments against drug-resistant pathogens in the future.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Raising Awareness About Men's Bone Health and Osteoporosis
June marks Men's Health Awareness Month, highlighting the often overlooked issue of osteoporosis in men. Early prevention, awareness, and treatment are key to maintaining healthy bones and avoiding dangerous fractures.
Research Reveals Lung Capacity Declines Starting Between Ages 20 and 25
New research shows that lung capacity begins to decline between ages 20 and 25, emphasizing the importance of early respiratory health monitoring and interventions.
Trump Administration Introduces New Private Health Data Tracking System with Tech Industry Collaboration
The Trump administration is launching a new private health tracking system in collaboration with major tech companies, aiming to improve access to medical records while raising significant privacy concerns.
New Study Reveals How Brain Aging Is Driven by Protein Production Disruptions in Killifish
A groundbreaking study using turquoise killifish reveals that disruptions in protein synthesis, particularly translation elongation, are key to brain aging and neurodegeneration. Insights from this research could lead to new therapies targeting age-related cognitive decline.